Earlier this month, Merck and Daiichi Sankyo announced that ifinatamab deruxtecan was granted Breakthrough Therapy Designation by the U.S. FDA for treating adult patients with extensive-stage small ...

Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung ...

Merck & Co (NYSE: MRK) and Daiichi Sankyo (TYO: 4568) have received Breakthrough Therapy designation from the US regulator ...

The Delhi High Court recently clarified that it does not have the power to directly attach immovable properties situated outside its territorial jurisdiction ev ...

Daiichi Sankyo Co. shares dropped the most in three months following a series of discounted block trades in the Japanese pharmaceutical company.

Merck agreed to pay Daiichi Sankyo $5.5 billion for the rights to jointly develop and commercialize three of its candidate cancer drugs, in a deal that could be worth up to $22 billion depending ...

In November 2019, Daiichi Sankyo filed a Declaratory Judgment action in the District Court of Delaware against Seagen in response to communications from Seagen claiming certain intellectual ...

Investors in the region are awaiting India's HSBC Composite flash purchasing managers' index reading for August expected ...

On December 23, 2020, Daiichi Sankyo filed a petition with the U.S. Patent Office for post-grant review contesting the patentability of certain claims within the ’039 patent. About Daiichi Sankyo ...

An AstraZeneca and Daiichi Sankyo cancer drug achieved one of the main goals of a Phase 3 study in non-small cell lung cancer. But patient deaths were also reported in the study, and the companies ...

Daiichi Sankyo now expects Enhertu could reach JPY 195.2 billion ($1.31 billion) sales in fiscal year 2022, a big increase from the previous JPY 128.4 billion forecast.